Mandate

Vinge advises Expedition Growth Capital in connection with investment in Xensam  

Expedition Growth Capital has today announced a $40 million growth investment in the Swedish SaaS company Xensam. Vinge acted as Expedition Growth Capital’s legal advisor in connection with the investment.

Xensam is a provider of an AI-powered Software Assessment Management (SAM) platform. The platform enables its customers to understand how users interact with applications, whether SaaS or on-premise, across the entire digital infrastructure to provide a comprehensive organisational overview across hybrid environments.

Expedition Growth Capital is a London-based growth fund focused on investing in fast-growing companies.

Vinge’s team consisted of Karl Klackenberg, Clara Sohlberg and Johan Gavelin (M&A), Rebecka Målquist (IP), Olivia Onwuta (Employment) and Anna Ekdahl Roos (Transaction Support).

 

Related

Vinge has advised EQT AB in connection with the refinancing of EQT’s EUR 1,500,000,000 sustainability-linked revolving credit facility

The sustainability-linked credit facility has a tenor of 5 years with two 1-year extension options.
July 23, 2024

Vinge has advised Embracer Group in connection with a EUR 600 million multicurrency revolving facility agreement

Vinge has advised Embracer Group in connection with a EUR 600 million multicurrency revolving facility agreement entered into with BNP Paribas, Citibank Europe, DNB, JP Morgan, Nordea, SEB and Swedbank.
July 19, 2024

Vinge has advised SBB and Sveafastigheter in connection with an exchange offer

Vinge has advised Samhällsbyggnadsbolaget i Norden AB (SBB) and Sveafastigheter AB in connection with an exchange offer directed to investors in SBB’s outstanding bonds, whereby investors exchanged senior and hybrid bonds in SBB for new senior bonds issued in Sveafastigheter AB. The existing bonds were partly issued under SBB’s EMTN programme, partly on a standalone basis. Following the transaction, the investors have been slotted in under Swedish bond terms on a standalone basis.
July 09, 2024